SCHEMBL23934284

SCHEMBL23934284

CN1C(=O)c2cc(NC(=O)c3ccc(C#N)cc3)cc(N)c2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
LMNA P02545 2/20 0.53
TP53 P04637 1/20 0.53
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
ESR1 P03372 1/20 0.45
MLYCD O95822 1/20 0.43
TLK2 Q86UE8 1/20 0.43
KCNH2 Q12809 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
NAMPT P43490 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
RPS6KA2 Q15349 1/20 0.41
ROCK2 O75116 1/20 0.40
F2 P00734 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934214 0.88 LMNA (0.53) MAPTLMNATP53CYP11B1CYP11B2
SCHEMBL27099939 0.87 POLB (0.50) MAPTLMNATP53MEN1NPC1
SCHEMBL23934285 0.84 ACE2 (0.48) MAPTLMNAMEN1NPC1RAB9A
SCHEMBL23934274 0.82 KMT2A (0.46) MAPTLMNATP53CYP11B1CYP11B2
SCHEMBL27099936 0.81 KMT2A (0.52) MAPTLMNACYP11B1CYP11B2MEN1
SCHEMBL27099941 0.80 ALDH1A1 (0.41) MAPTMEN1KMT2AALDH1A1
SCHEMBL27099938 0.79 KMT2A (0.49) MAPTTP53MEN1KMT2AALDH1A1
SCHEMBL23934265 0.77 POLB (0.50) MAPTLMNATP53CYP11B1CYP11B2
SCHEMBL27100057 0.77 CA12 (0.49) MAPTTP53MEN1NPC1RAB9A
SCHEMBL27100046 0.74 ALOX5 (0.49) MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 MAPT 1837/4885LMNA 4281/4885TP53 345/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 MAPT 1837/4885LMNA 4281/4885TP53 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.